Thera-SAbDab

ALEMTUZUMAB

>   Structural Summary
TherapeuticAlemtuzumab
TargetCD52
Heavy ChainQVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIK
100% seqID Fv Structure1bey [Fvs: HL], 1ce1 [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2000
INN Year Recommended2001
Companies InvolvedBayer HealthCare Pharmaceuticals Inc., Dana-Farber Cancer Institute, German CLL Study Group, Ohio State University Comprehensive Cancer Center, Sanofi, Sanofi Oncology, University of Cologne, University of Cambridge
Conditions ApprovedChronic lymphocytic leukaemia, Multiple sclerosis
Conditions ActiveLymphoma, T-cell prolymphocytic leukaemia
Conditions DiscontinuedRheumatoid arthritis, Diffuse large B cell lymphoma, Graft-versus-host disease, Sezary syndrome, T-cell lymphoma
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]